I was in Paris this week in the building of the Rare Disease Alliance, an association helping patients affected by a rare disease. The association lend their space to Neovacs, a biotech company from Paris, which was organising a gathering of experts of lupus.
Lupus is one of the most common rare disease and affects more than 5 million people worldwide. This meet-up was a good opportunity for me to talk with Prf. Jean Sibilia, Head of the National Reference Centre for Systemic Autoimmune Diseases and Miguel Sieler, CEO of Neovacs which develops a drug candidate against this disease.
Learn more in the video below!
More on Neovacs in these articles from Labiotech.eu:
- Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy
- Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins
Want to know more?
We’re preparing a special article to be published for World Lupus Day on May 10th. Stay tuned on Labiotech.eu!
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.